I-Mab
IMAB$870M
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaROCKVILLE32 employees
Drugs in Pipeline
4
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
IMAB News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
TJ003234
Coronavirus Disease 2019 COVID-19
TJ301 300mg
Active Ulcerative Colitis
TJ004309
Ovarian Cancer
Givastomig
Solid Tumor
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
TJ003234 | Phase 3 | Coronavirus Disease 2019 COVID-19 | - | - |
TJ301 300mg | Phase 2 | Active Ulcerative Colitis | - | - |
TJ004309 | Phase 2 | Ovarian Cancer | - | - |
Givastomig | Phase 2 | Solid Tumor | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply